Hyperacute Radiation Pneumonitis after Severe irAE

Author:

Chou Yang12,Chuang Wei-Kai34ORCID

Affiliation:

1. Department of Otolaryngology-Head and Neck Surgery, Shuang Ho Hospital, Taipei Medical University, New Taipei 23561, Taiwan

2. Department of Otolaryngology-Head and Neck Surgery, Taipei Medical University Hospital, Taipei 11031, Taiwan

3. Department of Radiation Oncology, Shuang Ho Hospital, Taipei Medical University, New Taipei 23561, Taiwan

4. Department of Biomedical Imaging and Radiological Sciences, National Yang Ming Chiao Tung University, Taipei 11221, Taiwan

Abstract

A 54-year-old woman presented to an outpatient clinic with a recurrence of triple-negative breast cancer and multiple bone metastases. The patient had a large mass lesion of 10 cm on the sternum. She received the immune checkpoint inhibitors pembrolizumab and taxane. Initially, the patient responded excellently to treatment, but stopped pembrolizumab for grade IV skin toxicity with multiple ulcerative wounds over the bilateral leg and trunk. The lesions abated following administration of antibiotics and oral prednisolone for two months. After that, she was referred to the radiation oncology department for further treatment. She received radiotherapy for the sternum mass but stopped radiation at 42Gy/21 fractions for severe dyspnea and fever. Blood sampling found leukocytosis with neutrophil predominance. Chest radiography showed bilateral lung infiltration. Pulmonary CT scan yielded bilateral lung patchy consolidation compatible with radiation isodose-line. Bronchial lavage showed positive Pneumocystis jiroveci PCR. Dyspnea improved after titrating methylprednisolone within two days. The patient recovered well with TMP-SMX and glucocorticoids after the initiation of therapy.

Publisher

MDPI AG

Reference6 articles.

1. Re-evaluating the risk factors for radiation pneumonitis in the era of immunotherapy;Chen;J. Transl. Med.,2023

2. Exclusion of emphysematous lung from dose-volume estimates of risk improves prediction of radiation pneumonitis;Uchida;Radiat. Oncol.,2017

3. Safety of Combined Immunotherapy and Thoracic Radiation Therapy: Analysis of 3 Single-Institutional Phase I/II Trials;Verma;Int. J. Radiat. Oncol. Biol. Phys.,2018

4. Comparison of Pneumonitis Rates and Severity in Patients with Lung Cancer Treated by Immunotherapy, Radiotherapy, and Immunoradiotherapy;Aiad;Cureus,2022

5. Lung Stereotactic Body Radiation Therapy and Concurrent Immunotherapy: A Multicenter Safety and Toxicity Analysis;Tian;Int. J. Radiat. Oncol. Biol. Phys.,2020

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

1. Methylprednisolone/pembrolizumab/prednisolone;Reactions Weekly;2024-06-01

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3